echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The phase report of "preclinical research on new antitumor drugs of Staphylococcus aureus enterotoxin C2 modified protein" was held

    The phase report of "preclinical research on new antitumor drugs of Staphylococcus aureus enterotoxin C2 modified protein" was held

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 9, the project of "preclinical research on new antitumor drugs of staphylococcal enterotoxin C2 modified protein", a major national science and technology project during the 12th Five Year Plan, hosted by Shenyang Institute of Applied Ecology, Chinese Academy of Sciences, held a stage report meeting in Shenyang Institute of Applied Ecology, Chinese Academy of Sciences More than 10 people attended the meeting, including academician Liu Changxiao of Tianjin Pharmaceutical Research Institute, chairman Chen juyu of Shenyang Xiehe Biological Pharmaceutical Co., Ltd., chairman Li Bingming of Dalian Tianyu Pharmaceutical Co., Ltd., researcher Zhang Chenggang of Shenyang Institute of Applied Ecology, Chinese Academy of Sciences, and backbone of related topics Zhang Huiwen, researcher of Shenyang Institute of Applied Ecology, Chinese Academy of Sciences, presided over the meeting At the seminar, researcher Zhang Huiwen focused on discussing the problems encountered in the current stage of the project with various experts Li Bingming, chairman of Dalian Tianyu Pharmaceutical Co., Ltd., expressed full support for the implementation of the task of the 12th Five Year Plan, and jointly undertook the task of the former Shenyang Xiehe biopharmaceutical Co., Ltd on the production of pilot new drug products and the long-term stability research and production of new drug products in line with the approval standard Chen juyu, chairman of Shenyang Xiehe biopharmaceutical Co., Ltd., took this meeting as an opportunity to introduce the new partners to the relevant project leaders, and to finalize the current task nodes of Xiehe and the project leaders Researcher Zhang Chenggang, as the representative of the overall project responsible unit, further clarified the three-party responsibilities of the project, and summarized the phased results according to the requirements of the task statement At last, academician Liu Changxiao made a concluding speech, stressing that the focus of the project should be strictly in accordance with the requirements of the State Food and Drug Administration (SFDA), and it should be carefully implemented Each subject unit should actively cooperate, communicate and cooperate in time, solve the problems as soon as possible, and complete the task of the 12th Five Year Plan on schedule After the meeting, participants visited the R & D Laboratory of Shenyang Xiehe Biological Pharmaceutical Co., Ltd  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.